Business Context and Reporting Period
Sotera Health Company filed a Form 8-K dated May 23, 2024, reporting the results of its 2024 Annual Meeting of Shareholders and an amendment to its Amended and Restated Certificate of Incorporation.
Key Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes
- Shareholders approved an amendment to Article VII, Section 1 of the Certificate of Incorporation to permit officer exculpation consistent with Delaware law.
- The amendment was filed with the Delaware Secretary of State and became effective on May 23, 2024.
- Four Class I director nominees were elected to serve until the 2027 annual meeting and until their successors are duly elected and qualified.
- Shareholders approved, on an advisory basis, the compensation of the named executive officers.
- Shareholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voting Results, Outlook, and Risks
Holders of 274,881,758 shares, representing 97.10% of the voting power as of the March 28, 2024 record date, were present in person or by proxy, constituting a quorum.
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Constantine S. Mihas | 247,637,962 | 25,121,299 | 199,643 | 1,922,854 |
| Election of James C. Neary | 247,632,361 | 25,124,250 | 202,293 | 1,922,854 |
| Election of Michael B. Petras, Jr. | 258,218,317 | 14,541,035 | 199,552 | 1,922,854 |
| Election of David E. Wheadon, M.D. | 251,978,688 | 20,939,001 | 41,215 | 1,922,854 |
| Named executive officer compensation | 267,658,420 | 5,255,645 | 44,839 | 1,922,854 |
| Ernst & Young LLP ratification | 274,569,360 | 272,260 | 40,138 | None |
| Officer exculpation amendment | 237,774,859 | 34,993,758 | 190,287 | 1,922,854 |
The filing contains no financial guidance or operating outlook. It also does not describe new business risks, contingencies, or unusual financial items. The officer exculpation provision may limit certain personal monetary liability of officers to the extent permitted by Delaware law; the filing does not describe its specific scope beyond that statutory consistency.
Important Facts to Verify
- Review Exhibit 3.1 for the exact language and scope of the officer exculpation amendment.
- Confirm the elected directors’ terms and any subsequent board appointments or changes.
- Review the company’s proxy statement dated April 11, 2024 for the detailed proposals, governance context, and executive compensation information.
- Use the company’s periodic reports for current financial performance, leverage, liquidity, guidance, and litigation or contingency disclosures, as those matters are not covered in this filing.